Top Page
SkinBioTherapeutics
(LSE:SBTX)
SkinBioTherapeutics (SBTX) vs. iShares MSCI United Kingdom ETF (EWC)
SkinBioTherapeutics Business Overview & Revenue Model
SkinBioTherapeutics Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.68M | 1.21M | 132.06K | 74.76K | 0.00 | 0.00 |
| Gross Profit | 1.45M | 683.04K | 85.19K | 15.91K | -5.05K | -5.10K |
| EBITDA | -2.28M | -2.72M | -2.96M | -2.95M | -1.49M | -1.61M |
| Net Income | -2.58M | -2.88M | -2.84M | -2.79M | -1.43M | -1.50M |
Balance Sheet | ||||||
| Total Assets | 7.30M | 5.22M | 2.59M | 3.08M | 5.73M | 2.77M |
| Cash, Cash Equivalents and Short-Term Investments | 1.24M | 800.90K | 1.31M | 1.80M | 4.61M | 2.16M |
| Total Debt | 1.03M | 818.74K | 100.65K | 127.86K | 139.85K | 0.00 |
| Total Liabilities | 2.81M | 2.25M | 599.34K | 609.61K | 519.67K | 304.83K |
| Stockholders Equity | 4.49M | 2.97M | 1.99M | 2.48M | 5.22M | 2.47M |
Cash Flow | ||||||
| Free Cash Flow | -2.22M | -2.92M | -2.81M | -2.77M | -1.67M | -965.80K |
| Operating Cash Flow | -2.20M | -2.73M | -2.65M | -2.67M | -1.56M | -892.14K |
| Investing Cash Flow | -3.72M | -2.30M | -165.28K | -96.81K | -112.31K | -73.67K |
| Financing Cash Flow | 4.32M | 4.51M | 2.32M | -35.12K | 4.12M | 0.00 |
SkinBioTherapeutics Technical Analysis
SkinBioTherapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | CHF22.60B | 15.13 | 10.81% | 2.13% | 47.85% | -11.82% | |
40 Underperform | £42.70M | ― | -63.28% | ― | 1557.07% | 24.70% | |
| £22.63M | 18.26 | 17.91% | ― | ― | ― | ||
| £11.62M | ― | -20.90% | ― | ― | ― | ||
47 Neutral | £26.21M | ― | -87.30% | ― | ― | 71.17% | |
| £20.30M | ― | -2.91% | ― | ― | ― | ||
| £63.16M | ― | -430.02% | ― | ― | ― |
SkinBioTherapeutics Corporate Events
SkinBioTherapeutics has announced an exclusive UK commercial agreement with Superdrug Stores plc for its AxisBiotix™ food supplements, aimed at alleviating inflammatory skin conditions. This partnership is expected to enhance the company’s market presence and distribution capabilities in the UK, potentially benefiting stakeholders by expanding the reach of its innovative skin health solutions.
David Campbell Brierwood has increased his voting rights in SkinBioTherapeutics PLC to 6.34%, up from a previous position of 5.561%. This acquisition of voting rights signifies a notable shift in shareholder influence, potentially impacting the company’s strategic decisions and stakeholder dynamics.
SkinBioTherapeutics plc has successfully raised approximately £4.2 million through a combination of a Placing, Subscription, and WRAP Retail Offer, issuing a total of 24,704,836 new Ordinary Shares at 17 pence per share. This capital raise will support the company’s operational and strategic initiatives, with the new shares expected to be admitted to trading on AIM by 24 June 2025, thereby increasing the company’s total voting rights and share capital.
SkinBioTherapeutics plc has announced a retail offer through the Winterflood Retail Access Platform to raise up to £0.62 million by issuing new ordinary shares. This offer is part of a broader fundraising effort, including a placing and subscription to raise approximately £4.1 million. The initiative aims to strengthen the company’s financial position and expand its operations, with the new shares expected to commence trading on AIM on June 24, 2025. This move underscores the company’s commitment to its retail shareholder base and its strategic growth in the skin health sector.
SkinBioTherapeutics has signed an exclusive UK commercial agreement with Superdrug for its AxisBiotix™ products, marking a significant milestone as it enters the national high street market. To support this agreement and future product development, the company has raised £4.1 million through a placing and subscription, with an additional proposed retail offer to existing shareholders. The AxisBiotix-Ps product has also received the US National Psoriasis Foundation’s Seal of Recognition, enhancing its credibility and market potential in the USA.
SkinBioTherapeutics plc has appointed Singer Capital Markets as its Nominated Adviser and Sole Broker, effective immediately. This strategic move is expected to enhance the company’s operational capabilities and market positioning, potentially benefiting stakeholders through improved advisory and brokerage services.
SkinBioTherapeutics PLC, a company involved in the biotechnology sector, has announced a change in its major holdings. The University of Manchester has reduced its voting rights in the company from 3.42% to 2.93%, as of April 29, 2025. This reduction in voting rights could impact the company’s shareholder dynamics and influence future decisions.
SkinBioTherapeutics PLC has announced a change in the breakdown of its voting rights, with Optibiotix Health plc now holding 7.95% of the voting rights, down from a previous 8.46%. This adjustment in voting rights reflects a shift in stakeholder influence within the company, potentially impacting its strategic decisions and governance.
SkinBioTherapeutics announced the exercise of warrants by Macquarie for 1,099,244 ordinary shares at £0.2043 per share, leaving no outstanding warrants with Macquarie. The new shares are expected to be admitted to AIM on May 1, 2025, increasing the total number of issued shares and voting rights to 234,074,627. This development may impact shareholder calculations under the Financial Conduct Authority’s rules, reflecting the company’s strategic financial maneuvers in the skin health industry.
SkinBioTherapeutics has appointed Simon Hewitson as Executive Director and Chief Operating Officer, effective immediately. This strategic move is expected to enhance the company’s operational capabilities and support its growth in the skin health sector, particularly as it continues to expand its product offerings and market reach.
SkinBioTherapeutics plc has announced significant changes in its leadership team, appointing Simon Hewitson as Chief Operating Officer and Emily Bertram as Group Finance Director. These changes aim to strengthen the company’s operational and financial functions amid an active M&A strategy and the launch of Croda Zenakine™. The appointments are expected to support the company’s growth and enhance its market position, with Hewitson’s extensive corporate finance experience and Bertram’s familiarity with the company’s financial systems being key assets.
SkinBioTherapeutics announced the successful global launch of Zenakine™ by Croda Beauty at the in-cosmetics Global 2025 meeting, receiving a standing ovation for its technical presentation. Zenakine™ offers benefits such as improved cell longevity, skin regeneration, and anti-aging effects. Despite the positive reception, the company noted an unexplained drop in share price. The management plans to discuss Zenakine™’s attributes and commercialization at an upcoming investor presentation, highlighting its potential impact on the company’s market position and stakeholder interests.
SkinBioTherapeutics announced that Croda plc has launched Zenakine™, a neuroactive ingredient designed to improve skin health by reducing stress effects and enhancing sleep quality, at the in-cosmetics Global exhibition. This launch marks a significant milestone for SkinBioTherapeutics, as Zenakine™ is the first ingredient with clinical measures on sleep benefits, offering a competitive edge in the cosmetics industry with its multifunctional and sustainable formulation options.
SkinBioTherapeutics PLC has announced a change in its major holdings, with Optibiotix Health plc reducing its voting rights from 9.58% to 8.46%. This adjustment in shareholding reflects a strategic shift and could impact the company’s governance and decision-making processes, potentially influencing its market position and stakeholder interests.